Successful treatment of intracranial hemorrhage with recombinant activated factor VII in a patient with newly diagnosed acute myeloid leukemia: A case report and review of the literature

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

© 2015 Pemmaraju, Sasaki, Johnson, Daver, Afshar-Kharghan, Chen, Ahmed, Colen, Kwon, Huh and Borthakur. Intracranial hemorrhage (ICH) is a common complication in acute myeloid leukemia (AML) patients with an incidence rate of 6.3% (1). Bleeding disorders related to disseminated intravascular coagulation (DIC) are common complications in AML cases (2). Recombinant activated Factor VII [rFVIIa (NovoSeven®)] is approved for the treatment of bleeding complications with FVIII or FIX inhibitors in patients with congenital FVII deficiency. Use of rFVIIa for the treatment of acute hemorrhage in patients without hemophilia has been successful (3, 4). Herein, we describe the successful use of rFVIIa in a patient with acute ICH in the setting of newly diagnosed AML.

Cite

CITATION STYLE

APA

Pemmaraju, N., Sasaki, K., Johnson, D., Daver, N., Afshar-Kharghan, V., Chen, M., … Borthakur, G. (2015). Successful treatment of intracranial hemorrhage with recombinant activated factor VII in a patient with newly diagnosed acute myeloid leukemia: A case report and review of the literature. Frontiers in Oncology, 5(FEB). https://doi.org/10.3389/fonc.2015.00029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free